Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Merck_&_Co.
|
| gptkbp:acquisitionYear |
2021
|
| gptkbp:ceased_operations |
2021
|
| gptkbp:focusesOn |
oncology
hematology pulmonary diseases therapeutics for rare diseases |
| gptkbp:foundedIn |
2003
|
| gptkbp:founder |
gptkb:Mark_Ptashne
gptkb:Jasbir_Seehra gptkb:John_Knopf gptkb:Tom_Maniatis |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Acceleron Pharma
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:luspatercept
gptkb:sotatercept |
| gptkbp:stockSymbol |
gptkb:XLRN
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.acceleronpharma.com/
|
| gptkbp:bfsParent |
gptkb:Polaris_Partners
|
| gptkbp:bfsLayer |
4
|